Battelle acquires nearly 11 percent of AMIC’s exceptional Common Stock Advanced Medical Isotope Company , a past due stage development company involved primarily in the advancement of brachytherapy products and medical isotopes for diagnostic and therapeutic applications, announced that Battelle today, has acquired around 11 percent of AMIC's outstanding Common Share detox alcohol http://revia.org/ . Battelle is a respected international technology and technology business that explores emerging regions of research and evolves and commercializes technology. In 2011, AMIC entered into permit agreements with Battelle for 10 patents linked to AMICs brachytherapy items; and in 2012, AMIC entered into a special license contract with Battelle for usage of Battelle's patented brachytherapy gel technology.

naltrexone hcl 50mg

Barr Pharmaceuticals receives authorization for generic Taxol injection Barr Pharmaceuticals, Inc.s., provides received final authorization from the U.S. Food and Medication Administration because of its generic edition of Bristol-Myers Squibb Company’s Taxol Injection USP, 6mg/mL, packaged in 100mg/16.7 mL and 300mg/50 mL Multiple-dose Vials. THE BUSINESS plans to shortly start its product. Barr’s U.S. Generic injectable portfolio totals seven products. Barr’s item will compete in market that got annual sales of around $98 million for the a year ended January 2008, predicated on IMS sales data.